Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp WT (BCTXW)

Briacell Therapeutics Corp WT (BCTXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,310 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/11/26 [--]
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0017 +252.94%
on 02/06/26
0.0260 -76.92%
on 01/20/26
-0.0209 (-77.70%)
since 01/16/26
3-Month
0.0017 +252.94%
on 02/06/26
0.0631 -90.49%
on 01/05/26
-0.0403 (-87.04%)
since 11/19/25
52-Week
0.0017 +252.94%
on 02/06/26
0.2500 -97.60%
on 04/24/25
-0.1239 (-95.38%)
since 02/19/25

Most Recent Stories

More News
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Fifth consecutive positive DSMB...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022   remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations ...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTXL : 1.0000 (-3.85%)
BCTX : 4.13 (+3.51%)
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTX : 4.13 (+3.51%)
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTX : 4.13 (+3.51%)
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTX : 4.13 (+3.51%)
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Enrollment exceeding expectations with strong clinical site and patient...

BCT.TO : 5.64 (+3.49%)
BCTXW : 0.0060 (+3.45%)
BCTXZ : 0.1453 (+3.79%)
BCTX : 4.13 (+3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar